Trading update highlights Salmosan generic BMK interim results, and FY2015 results, are expected to suffer through the impact of a Salmosan generic on sale in Chile. Pipeline delays add to the potential shortfall in revenues and profits. On the plus side, the new Breeding & Genetics division is performing strongly, even against FX headwinds.
05 May 2015
Generic speed bumps, but clear growth path
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Generic speed bumps, but clear growth path
Benchmark Holdings Plc (BMK:LON) | 43.2 0.1 0.6% | Mkt Cap: 319.9m
- Published:
05 May 2015 -
Author:
Robin Campbell -
Pages:
9
Trading update highlights Salmosan generic BMK interim results, and FY2015 results, are expected to suffer through the impact of a Salmosan generic on sale in Chile. Pipeline delays add to the potential shortfall in revenues and profits. On the plus side, the new Breeding & Genetics division is performing strongly, even against FX headwinds.